ReviewEuropean respiratory review : an official journal of the European Respiratory Society2019
Cancer-associated thrombosis: the when, how and why.
Review in European respiratory review : an official journal of the European Respiratory Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05729464 (Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism), which is not on this map. Cited by 180 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism
Who cites it
180 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Pharmacoeconomic evaluation of direct oral anticoagulants for cancer-associated thrombosis: a systematic review.Frontiers in public health · 2025Pooled it
- Efficacy and safety of different treatments in chemotherapy-induced thrombocytopenia: a systematic review and network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Brazilian guidelines for the pharmacological treatment of pulmonary embolism. Official document of the Brazilian Thoracic Association based on the GRADE methodology.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Guideline
- Incidence and risk factors of VTE in lung cancer: a meta-analysis.Annals of medicine · 2024Pooled it
- Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis.BMC pharmacology & toxicology · 2023Pooled it
- Relation of Mean Platelet Volume (MPV) with Cancer: A Systematic Review with a Focus on Disease Outcome on Twelve Types of Cancer.Current oncology (Toronto, Ont.) · 2023Pooled it
- The D-dimer level predicts the prognosis in patients with lung cancer: a systematic review and meta-analysis.Journal of cardiothoracic surgery · 2021Pooled it
- Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review.Frontiers in cardiovascular medicine · 2021Pooled it
- Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.The oncologist · 2023Trial
- Identifying Predictors of Delayed Ambulation After Minimally Invasive Gynecologic Oncology Surgery.Annals of surgical oncology · 2026Article
- Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs.Research and practice in thrombosis and haemostasis · 2026Article
- Persistent Hypercoagulability After Radical Prostatectomy: Biomarker Dynamics and Implications for Individualized Thromboprophylaxis.Journal of clinical medicine · 2026Review
- No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects.International journal of cancer · 2026Article
- Current Knowledge of Immune Checkpoint Inhibitor-Induced Thrombocytopenia: Epidemiology, Mechanisms, and Management.Cancer medicine · 2026Review
- Systemic immune-inflammation index as a predictor of venous thromboembolism in NSCLC patients treated with ICIs: a retrospective study.BMC pulmonary medicine · 2026Article
- Anticoagulation challenges in cancer patients: prevention, detection, and treatment strategies.Cardio-oncology (London, England) · 2026Review
- Polycationic dendrimers synergizes with gefitinib to overcome EGFRDiscover oncology · 2026Article
- Mitochondrial IκBα fuels cancer progression through metabolic rewiring, endothelial activation, and thrombotic spread.Cell death discovery · 2026Article
- Trousseau Syndrome Associated With Prostate Cancer: A Systematic Review of Case Reports.Cureus · 2026Review
- Identification of novel ceRNA networks associated with system hemostasis and their prognostic implication in lung squamous cell carcinoma.Journal of thrombosis and thrombolysis · 2026Article
120 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated thrombosis (CAT) is a condition in which relevance has been increasingly recognised both for physicians that deal with venous thromboembolism (VTE) and for oncologists. It is currently estimated that the annual incidence of VTE in patients with cancer is 0.5% compared to 0.1% in the general population. Active cancer accounts for 20% of the overall incidence of VTE. Of note, VTE is the second most prevalent cause of death in cancer, second only to the progression of the disease, and cancer is the most prevalent cause of deaths in VTE patients. Nevertheless, CAT presents several peculiarities that distinguish it from other VTE, both in pathophysiology mechanisms, risk factors and especially in treatment, which need to be considered. CAT data will be reviewed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.